Evidence map›Paper›PMID 37441544›Full record

ArticleClinical and translational radiation oncology2023

Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial.

Iris Bartula, Anh D Tran, Anna K Nowak, Tasnia Ahmed, Rachael L Morton, Bryan H Burmeister, Kari Dolven-Jacobsen, Jenny Nobes, John F Thompson, Gerald B Fogarty and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01503827 (Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma - A Randomised Phase III Trial), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01503827 naunknown statusnot on this map

Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma - A Randomised Phase III Trial

TypeinterventionalSponsorMelanoma and Skin Cancer Trials LimitedRan2007 to 2022Enrolled220ConditionsMetastatic MelanomaArmsWBRT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 4 countries.

Iris BartulaMelanoma Institute Australia, The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2067, Australia.
Anh D TranNational Drug and Alcohol Research Centre, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.
Anna K NowakMedical School, The University of Western Australia, 35 Stirling Hwy, 35 Stirling Highway, Perth, WA 6009, Australia.
Tasnia AhmedSchool of Population Health, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.
Rachael L MortonMelanoma Institute Australia, The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2067, Australia.
Bryan H BurmeisterGenesisCare Fraser Coast, 1 Medical Place, Urraween, Qld 4655, Australia.
Kari Dolven-JacobsenOslo University Hospital, The Radium Hospital, P. O. Box 4953 Nydalen, N-0424 Oslo, Norway.
Jenny NobesNorfolk and Norwich University Hospitals, Colney Lane, Norwich NR4 7UY, UK.
John F ThompsonMelanoma Institute Australia, The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2067, Australia.
Gerald B FogartyGenesiscare, Radiation Oncology, Mater Hospital 22 Rocklands Road, North Sydney, NSW 2067, Australia.
Serigne N LoMelanoma Institute Australia, The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2067, Australia.
Angela M HongMelanoma Institute Australia, The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2067, Australia.
The University of Sydney · AUUNSW Sydney · AUCooperative Trials Group for Neuro-Oncology · AUMater Health Services · AUNorfolk and Norwich University Hospital · GBOslo University Hospital · NOThe University of Queensland · AUUniversity of Stirling · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Brain metastases are common in patients with advanced melanoma. This study describes 12-month quality of life (QoL) trajectories following local management of 1-3 melanoma brain metastases. Methods: This study assessed QoL data collected during a multi-center, prospective, open-label, phase III randomized controlled trial comparing the efficacy of adjuvant whole brain radiotherapy (WBRT) with observation after local treatment of 1-3 melanoma brain metastases. Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Core (QLQ-C30) and Brain Tumour (BN-20) questionnaires at baseline and every 2 months, for 12 months.Using growth mixture modelling, QoL trajectories were identified for global health status, QLQ-C30 and BN-20 subscales for patients with baseline and at least one follow-up assessment. Multivariable logistic regression was used to examine associations between trajectories, demographic, and clinical factors. Results: After combining QoL data from observation and WBRT arms, QLQ-C30 and BN-20 trajectories were calculated for 139 and 137 patients respectively. Depending on the QoL domain, 9-54 % of patients reported a deterioration in QoL. Older age (≥65 years) was significantly associated with deterioration in global health status (OR = 2.88, 95 %CI = 1.27-6.54), physical (OR = 3.49, 95 %CI = 1.29-9.41), role (OR = 4.15, 95 %CI = 1.77-9.71), social (OR = 4.42, 95 % CI = 1.57-12.46), cognitive (OR = 6.70, 95 % CI = 1.93-23.29) and motor functioning (OR = 4.95, 95 %CI = 1.95-12.61) and increased future uncertainty (OR = 0.20, 95 %CI = 0.07-0.53). Female sex (OR = 0.10, 95 %CI = 0.02-0.41), not having neurosurgery at baseline (OR = 0.09, 95 %CI = 0.02-0.52), 2-3 brain metastases (OR = 5.75, 95 %CI = 1.76-18.85) or receiving adjuvant WBRT (OR = 6.77, 95 %CI = 2.00-22.99) were associated with poorer physical, emotional, cognitive and social outcomes respectively. Conclusions: Poorer QoL outcomes in the first 12 months after diagnosis of melanoma brain metastases were observed in patients aged ≥ 65 years, females, having 2-3 brain metastases, non-surgical treatment of metastases or adjuvant WBRT.Clinical Trial Registration Number:Whole Brain Radiotherapy Trial (WBRTMel) was registered with the Australian Clinical Trials Registry (ACTRN12607000512426) and ClinicalTrials.gov (NCT01503827).Study Support:This project was funded by Cancer Australia PdCCRS (Grants No. 512358, 1009485, and 1084046) and the National Helath and Medical Research Coucil of Australia (NHMRC; Grant No. 1135285).ADT was supported by a Cancer Australia Priority-driven Collaborative Cancer Research Scheme. Project #1046923. RLM was supported by an NHMRC Fellowship #1194703 and a University of Sydney, Robinson Fellowship. JFT was supported by an NHMRC Program Grant #1093017.

Indexed as

Brain NeoplasmsMelanomaQuality of LifeRadiotherapy

Identifiers

PMID37441544
PMCPMC10334158
OpenAlexW4320912661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.